首页 > 最新文献

International Journal of Toxicology最新文献

英文 中文
In vitro Safety Assessment of Extracts and Compounds From Plants as Sunscreen Ingredients. 植物提取物和化合物作为防晒成分的体外安全性评估。
IF 2.2 4区 医学 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-05-01 Epub Date: 2024-01-06 DOI: 10.1177/10915818231225661
Silvia Juliana Flórez González, Elena E Stashenko, Raquel Elvira Ocazionez, María Pilar Vinardell, Jorge Luis Fuentes

This work investigated the safety of extracts obtained from plants growing in Colombia, which have previously shown UV-filter/antigenotoxic properties. The compounds in plant extracts obtained by the supercritical fluid (CO2) extraction method were identified using gas chromatography coupled to mass spectrometry (GC/MS) analysis. Cytotoxicity measured as cytotoxic concentration 50% (CC50) and genotoxicity of the plant extracts and some compounds were studied in human fibroblasts using the trypan blue exclusion assay and the Comet assay, respectively. The extracts from Pipper eriopodon and Salvia aratocensis species and the compound trans-β-caryophyllene were clearly cytotoxic to human fibroblasts. Conversely, Achyrocline satureioides, Chromolaena pellia, and Lippia origanoides extracts were relatively less cytotoxic with CC50 values of 173, 184, and 89 μg/mL, respectively. The C. pellia and L. origanoides extracts produced some degree of DNA breaks at cytotoxic concentrations. The cytotoxicity of the studied compounds was as follows, with lower CC50 values representing the most cytotoxic compounds: resveratrol (91 μM) > pinocembrin (144 μM) > quercetin (222 μM) > titanium dioxide (704 μM). Quercetin was unique among the compounds assayed in being genotoxic to human fibroblasts. Our work indicates that phytochemicals can be cytotoxic and genotoxic, demonstrating the need to establish safe concentrations of these extracts for their potential use in cosmetics.

这项研究调查了从哥伦比亚生长的植物中提取的萃取物的安全性,这些植物曾显示出紫外线过滤/抗原毒性特性。通过超临界流体(CO2)萃取法获得的植物提取物中的化合物采用气相色谱-质谱联用(GC/MS)分析法进行了鉴定。利用胰蓝排除法和彗星试验,分别研究了植物提取物和一些化合物在人成纤维细胞中的细胞毒性(以细胞毒性浓度 50%(CC50)计)和遗传毒性。Pipper eriopodon 和 Salvia aratocensis 的提取物以及化合物 trans-β-caryophyllene 对人类成纤维细胞具有明显的细胞毒性。相反,Achyrocline satureioides、Chromolaena pellia 和 Lippia origanoides 提取物的细胞毒性相对较低,CC50 值分别为 173、184 和 89 μg/mL。在细胞毒性浓度下,C. pellia 和 L. origanoides 提取物会产生一定程度的 DNA 断裂。研究化合物的细胞毒性如下,CC50 值越低,代表化合物的细胞毒性越强:白藜芦醇(91 μM)>松果菊素(144 μM)>槲皮素(222 μM)>二氧化钛(704 μM)。在所检测的化合物中,槲皮素对人类成纤维细胞的基因毒性是独一无二的。我们的研究结果表明,植物化学物质可能具有细胞毒性和基因毒性,因此有必要确定这些提取物的安全浓度,以便将其用于化妆品。
{"title":"In vitro Safety Assessment of Extracts and Compounds From Plants as Sunscreen Ingredients.","authors":"Silvia Juliana Flórez González, Elena E Stashenko, Raquel Elvira Ocazionez, María Pilar Vinardell, Jorge Luis Fuentes","doi":"10.1177/10915818231225661","DOIUrl":"10.1177/10915818231225661","url":null,"abstract":"<p><p>This work investigated the safety of extracts obtained from plants growing in Colombia, which have previously shown UV-filter/antigenotoxic properties. The compounds in plant extracts obtained by the supercritical fluid (CO<sub>2</sub>) extraction method were identified using gas chromatography coupled to mass spectrometry (GC/MS) analysis. Cytotoxicity measured as cytotoxic concentration 50% (CC<sub>50</sub>) and genotoxicity of the plant extracts and some compounds were studied in human fibroblasts using the trypan blue exclusion assay and the Comet assay, respectively. The extracts from <i>Pipper eriopodon</i> and <i>Salvia aratocensis</i> species and the compound <i>trans</i>-β-caryophyllene were clearly cytotoxic to human fibroblasts. Conversely, <i>Achyrocline satureioides</i>, <i>Chromolaena pellia</i>, and <i>Lippia origanoides</i> extracts were relatively less cytotoxic with CC<sub>50</sub> values of 173, 184, and 89 μg/mL, respectively. The <i>C. pellia</i> and <i>L. origanoides</i> extracts produced some degree of DNA breaks at cytotoxic concentrations. The cytotoxicity of the studied compounds was as follows, with lower CC<sub>50</sub> values representing the most cytotoxic compounds: resveratrol (91 μM) > pinocembrin (144 μM) > quercetin (222 μM) > titanium dioxide (704 μM). Quercetin was unique among the compounds assayed in being genotoxic to human fibroblasts. Our work indicates that phytochemicals can be cytotoxic and genotoxic, demonstrating the need to establish safe concentrations of these extracts for their potential use in cosmetics.</p>","PeriodicalId":14432,"journal":{"name":"International Journal of Toxicology","volume":" ","pages":"243-252"},"PeriodicalIF":2.2,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139110948","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Safety Assessment of Streptococcus salivarius UBSS-01 in Rats and Double-Blind Placebo-Controlled Study in Healthy Individuals 唾液链球菌 UBSS-01 在大鼠中的安全性评估和在健康人中的双盲安慰剂对照研究
IF 2.2 4区 医学 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-04-27 DOI: 10.1177/10915818241247527
Bindhu S. Jatoth, Ziaur Rahman, Manoj P. Dandekar, Rajesh Venkataraman, Ravi K. Shivalingegowda, Gloriya G. Manuel
Streptococcus salivarius is a common, harmless, and prevalent member of the oral microbiota in humans. In the present study, the safety of S. salivarius UBSS-01 was evaluated using in silico methods and preclinical and clinical studies. In an acute toxicity study, rats were administered with 5 g/kg (500 × 109 CFU) S. salivarius UBSS-01. The changes in phenotypic behaviors and hematological, biochemical, electrolytes, and urine analyses were monitored. No toxicity was observed at 14 days post-treatment. The no observable effects limit (NOEL) of S. salivarius UBSS-01 was >5 g/kg in rats. In a 28-day repeat dose toxicity study, rats were administered S. salivarius UBSS-01 once daily at doses of 0.1, 0.5, and 1 g/kg (10, 50, and 100 billion CFU/kg, respectively) body weight. S. salivarius UBSS-01 did not influence any of the hematology parameters and clinical chemistry parameters in plasma and serum samples after 28-day repeated administration. No structural abnormality was observed in the histological examination of organs. Whole genome analysis revealed the absence of virulence factors or genes that may transmit antibiotic resistance. In the double-blind study with 60 human participants (aged 18–60 years), consumption of S. salivarius UBSS-01 for 30 days was found to be safe and results were comparable with placebo treatment These findings indicate that S. salivarius UBSS-01 may be safe for human consumption.
唾液链球菌是人类口腔微生物群中常见、无害且普遍的成员。本研究采用硅学方法和临床前及临床研究对唾液链球菌 UBSS-01 的安全性进行了评估。在急性毒性研究中,大鼠每公斤摄入 5 克(500 × 109 CFU)唾液酸酵母菌 UBSS-01。研究人员监测了大鼠的表型行为变化以及血液、生化、电解质和尿液分析。治疗后 14 天未观察到毒性。唾液腺单胞菌 UBSS-01 对大鼠的无观测效应限(NOEL)为 5 克/千克。在一项为期 28 天的重复剂量毒性研究中,按 0.1、0.5 和 1 克/千克(分别为 100、500 和 1000 亿 CFU/千克)的体重剂量给大鼠每天注射一次唾液球菌 UBSS-01。重复给药 28 天后,唾液球菌 UBSS-01 没有影响血浆和血清样本中的任何血液学参数和临床化学参数。器官组织学检查未发现结构异常。全基因组分析表明,不存在可能传播抗生素耐药性的毒力因子或基因。在对 60 名人类参与者(18-60 岁)进行的双盲研究中发现,连续 30 天食用唾液腺战士 UBSS-01 是安全的,其结果与安慰剂治疗相当。
{"title":"Safety Assessment of Streptococcus salivarius UBSS-01 in Rats and Double-Blind Placebo-Controlled Study in Healthy Individuals","authors":"Bindhu S. Jatoth, Ziaur Rahman, Manoj P. Dandekar, Rajesh Venkataraman, Ravi K. Shivalingegowda, Gloriya G. Manuel","doi":"10.1177/10915818241247527","DOIUrl":"https://doi.org/10.1177/10915818241247527","url":null,"abstract":"Streptococcus salivarius is a common, harmless, and prevalent member of the oral microbiota in humans. In the present study, the safety of S. salivarius UBSS-01 was evaluated using in silico methods and preclinical and clinical studies. In an acute toxicity study, rats were administered with 5 g/kg (500 × 10<jats:sup>9</jats:sup> CFU) S. salivarius UBSS-01. The changes in phenotypic behaviors and hematological, biochemical, electrolytes, and urine analyses were monitored. No toxicity was observed at 14 days post-treatment. The no observable effects limit (NOEL) of S. salivarius UBSS-01 was &gt;5 g/kg in rats. In a 28-day repeat dose toxicity study, rats were administered S. salivarius UBSS-01 once daily at doses of 0.1, 0.5, and 1 g/kg (10, 50, and 100 billion CFU/kg, respectively) body weight. S. salivarius UBSS-01 did not influence any of the hematology parameters and clinical chemistry parameters in plasma and serum samples after 28-day repeated administration. No structural abnormality was observed in the histological examination of organs. Whole genome analysis revealed the absence of virulence factors or genes that may transmit antibiotic resistance. In the double-blind study with 60 human participants (aged 18–60 years), consumption of S. salivarius UBSS-01 for 30 days was found to be safe and results were comparable with placebo treatment These findings indicate that S. salivarius UBSS-01 may be safe for human consumption.","PeriodicalId":14432,"journal":{"name":"International Journal of Toxicology","volume":"10 1","pages":""},"PeriodicalIF":2.2,"publicationDate":"2024-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140812420","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Dose Range-Finding Toxicity Study in Rats With Recombinant Human Lactoferrin Produced in Komagataella phaffii 用 Komagataella phaffii 生产的重组人乳铁蛋白对大鼠进行剂量范围毒性研究
IF 2.2 4区 医学 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-04-22 DOI: 10.1177/10915818241247013
Ross Peterson, Robert B. Crawford, Lance K. Blevins, Norbert E. Kaminski, June S. Sass, Bryce Ferraro, Roma Vishwanath-Deutsch, Anthony J. Clark, Carrie-Anne Malinczak
The oral toxicity of recombinant human lactoferrin (rhLF, Helaina rhLF, Effera™) produced in Komagataella phaffii was investigated in adult Sprague Dawley rats by once daily oral gavage for 14 consecutive days. The study used groups of 3–6 rats/sex/dose. The vehicle control group received sodium citrate buffer, and the test groups received daily doses of 200, 1000, and 2000 mg of rhLF in sodium citrate buffer per kg body weight. Bovine LF at 2000 mg/kg body weight per day was used as a comparative control. Clinical observations, body weight, hematology, clinical chemistry, iron parameters, immunophenotyping, and gross examination at necropsy were used as criteria for detecting the effects of treatment in all groups and to help select dose levels for future toxicology studies. Quantitative LF levels were also analyzed as an indication of bioavailability. Overall, administration of Helaina rhLF by once daily oral gavage for 14 days was well tolerated in rats at levels up to 2000 mg/kg/day, or 57 × Helaina’s intended commercial use in adults, and indicating that a high dose of 2000 mg/kg/day is appropriate for future definitive toxicology studies.
研究人员以成年 Sprague Dawley 大鼠为研究对象,连续 14 天每天一次口服 Komagataella phaffii 中生产的重组人乳铁蛋白(rhLF、Helaina rhLF、Effera™)。研究采用 3-6 只大鼠/性别/剂量分组。载体对照组接受柠檬酸钠缓冲液,试验组接受柠檬酸钠缓冲液中的 rhLF,每日剂量分别为每公斤体重 200、1000 和 2000 毫克。每天每公斤体重 2000 毫克的牛血清磷脂作为对比对照。临床观察、体重、血液学、临床化学、铁参数、免疫分型和尸体解剖时的大体检查被用作检测所有组治疗效果的标准,并帮助选择未来毒理学研究的剂量水平。此外,还分析了LF的定量水平,作为生物利用率的指标。总体而言,大鼠对每日一次口服海拉那(Helaina)rhLF 14天的耐受性良好,最高剂量为2000毫克/千克/天,相当于海拉那(Helaina)在成人中的预期商业用量的57倍,这表明2000毫克/千克/天的高剂量适合用于未来的确定性毒理学研究。
{"title":"Dose Range-Finding Toxicity Study in Rats With Recombinant Human Lactoferrin Produced in Komagataella phaffii","authors":"Ross Peterson, Robert B. Crawford, Lance K. Blevins, Norbert E. Kaminski, June S. Sass, Bryce Ferraro, Roma Vishwanath-Deutsch, Anthony J. Clark, Carrie-Anne Malinczak","doi":"10.1177/10915818241247013","DOIUrl":"https://doi.org/10.1177/10915818241247013","url":null,"abstract":"The oral toxicity of recombinant human lactoferrin (rhLF, Helaina rhLF, Effera™) produced in Komagataella phaffii was investigated in adult Sprague Dawley rats by once daily oral gavage for 14 consecutive days. The study used groups of 3–6 rats/sex/dose. The vehicle control group received sodium citrate buffer, and the test groups received daily doses of 200, 1000, and 2000 mg of rhLF in sodium citrate buffer per kg body weight. Bovine LF at 2000 mg/kg body weight per day was used as a comparative control. Clinical observations, body weight, hematology, clinical chemistry, iron parameters, immunophenotyping, and gross examination at necropsy were used as criteria for detecting the effects of treatment in all groups and to help select dose levels for future toxicology studies. Quantitative LF levels were also analyzed as an indication of bioavailability. Overall, administration of Helaina rhLF by once daily oral gavage for 14 days was well tolerated in rats at levels up to 2000 mg/kg/day, or 57 × Helaina’s intended commercial use in adults, and indicating that a high dose of 2000 mg/kg/day is appropriate for future definitive toxicology studies.","PeriodicalId":14432,"journal":{"name":"International Journal of Toxicology","volume":"29 1","pages":""},"PeriodicalIF":2.2,"publicationDate":"2024-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140804396","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Recovery Animals in Toxicology Studies: An Innovation and Quality Consortium Perspective on Best Practices With Case Study Examples 恢复毒理学研究中的动物:创新与质量联合会的最佳实践视角及案例研究实例
IF 2.2 4区 医学 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-04-12 DOI: 10.1177/10915818241243350
Smita Salian-Mehta, James D. Smith, Thierry D. Flandre, Amy L. Lambert, Joan H. Lane, Alan H. Stokes, Kathy Orsted, Natalie A. Bratcher-Petersen, Kyathanahalli S. Janardhan, Elizabeth G. Tonkin
The inclusion of recovery animals in nonclinical safety studies that support clinical trials is undertaken with a wide diversity of approaches even while operating under harmonized regulatory guidance. While empirical evaluation of reversibility may enhance the overall nonclinical risk assessment, there are often overlooked opportunities to reduce recovery animal use by leveraging robust scientific and regulatory information. In the past, there were several attempts to benchmark recovery practices; however, recommendations have not been consistently applied across the pharmaceutical industry. A working group (WG) sponsored by the 3Rs Translational and Predictive Sciences Leadership Group of the IQ Consortium conducted a survey of current industry practice related to the evaluation of reversibility/recovery in repeat dose toxicity studies. Discussion among the WG representatives included member company strategies and case studies that highlight challenges and opportunities for continuous refinements in the use of recovery animals. The case studies presented in this paper demonstrate increasing alignment with the Society of Toxicologic Pathology recommendations (2013) towards (1) excluding recovery phase cohorts by default (include only when scientifically justified), (2) minimizing the number of recovery groups (e.g., control and one dose level), and (3) excluding controls in the recovery cohort by leveraging external and/or dosing phase data. Recovery group exclusion and decisions regarding the timing of reversibility evaluation may be driven by indication, modality, and/or other scientific or strategic factors using a weight of evidence approach. The results and recommendations discussed present opportunities to further decrease animal use without impacting the quality of human risk assessment.
在支持临床试验的非临床安全性研究中使用恢复期动物的方法多种多样,即使是在统一的监管指导下也是如此。虽然对可逆性的经验评估可能会加强整体的非临床风险评估,但人们往往忽视了通过利用可靠的科学和监管信息来减少复原动物使用的机会。过去,人们曾多次尝试为恢复实践制定基准;但是,这些建议并没有在整个制药行业得到一致应用。由 IQ 联合会 3Rs 转化和预测科学领导小组赞助的一个工作组(WG)对当前行业中与重复剂量毒性研究中的可逆性/恢复性评估相关的实践进行了调查。工作组代表讨论的内容包括成员公司的策略和案例研究,这些策略和案例研究突出了在使用恢复期动物方面不断改进所面临的挑战和机遇。本文中介绍的案例研究表明,与毒理学病理学会的建议(2013 年)越来越一致,即:(1) 默认排除恢复期队列(仅在科学上合理时才纳入);(2) 尽量减少恢复组的数量(例如对照组和一个剂量水平);(3) 利用外部和/或剂量阶段数据排除恢复队列中的对照组。恢复组的排除和有关可逆性评估时机的决定可能受适应症、方式和/或其他科学或战略因素的驱动,采用证据权重法。所讨论的结果和建议为在不影响人类风险评估质量的情况下进一步减少动物使用提供了机会。
{"title":"Recovery Animals in Toxicology Studies: An Innovation and Quality Consortium Perspective on Best Practices With Case Study Examples","authors":"Smita Salian-Mehta, James D. Smith, Thierry D. Flandre, Amy L. Lambert, Joan H. Lane, Alan H. Stokes, Kathy Orsted, Natalie A. Bratcher-Petersen, Kyathanahalli S. Janardhan, Elizabeth G. Tonkin","doi":"10.1177/10915818241243350","DOIUrl":"https://doi.org/10.1177/10915818241243350","url":null,"abstract":"The inclusion of recovery animals in nonclinical safety studies that support clinical trials is undertaken with a wide diversity of approaches even while operating under harmonized regulatory guidance. While empirical evaluation of reversibility may enhance the overall nonclinical risk assessment, there are often overlooked opportunities to reduce recovery animal use by leveraging robust scientific and regulatory information. In the past, there were several attempts to benchmark recovery practices; however, recommendations have not been consistently applied across the pharmaceutical industry. A working group (WG) sponsored by the 3Rs Translational and Predictive Sciences Leadership Group of the IQ Consortium conducted a survey of current industry practice related to the evaluation of reversibility/recovery in repeat dose toxicity studies. Discussion among the WG representatives included member company strategies and case studies that highlight challenges and opportunities for continuous refinements in the use of recovery animals. The case studies presented in this paper demonstrate increasing alignment with the Society of Toxicologic Pathology recommendations (2013) towards (1) excluding recovery phase cohorts by default (include only when scientifically justified), (2) minimizing the number of recovery groups (e.g., control and one dose level), and (3) excluding controls in the recovery cohort by leveraging external and/or dosing phase data. Recovery group exclusion and decisions regarding the timing of reversibility evaluation may be driven by indication, modality, and/or other scientific or strategic factors using a weight of evidence approach. The results and recommendations discussed present opportunities to further decrease animal use without impacting the quality of human risk assessment.","PeriodicalId":14432,"journal":{"name":"International Journal of Toxicology","volume":"1 1","pages":""},"PeriodicalIF":2.2,"publicationDate":"2024-04-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140577692","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Editor’s Note 编者按
IF 2.2 4区 医学 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-04-04 DOI: 10.1177/10915818241245479
Mary Beth Genter
{"title":"Editor’s Note","authors":"Mary Beth Genter","doi":"10.1177/10915818241245479","DOIUrl":"https://doi.org/10.1177/10915818241245479","url":null,"abstract":"","PeriodicalId":14432,"journal":{"name":"International Journal of Toxicology","volume":"86 1","pages":""},"PeriodicalIF":2.2,"publicationDate":"2024-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140577623","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Safety Assessment of Zinc Salts as Used in Cosmetics. 化妆品中使用的锌盐的安全性评估。
IF 2.2 4区 医学 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-04-01 Epub Date: 2024-01-27 DOI: 10.1177/10915818241227124
Laura N Scott, Monice Fiume, Jinqiu Zhu, Wilma F Bergfeld, Donald V Belsito, Ronald A Hill, Curtis D Klaassen, Daniel C Liebler, James G Marks, Ronald C Shank, Thomas J Slaga, Paul W Snyder, Bart Heldreth

The Expert Panel for Cosmetic Ingredient Safety (Panel) assessed the safety of 27 inorganic and organometallic zinc salts as used in cosmetic formulations; these salts are specifically of the 2+ (II) oxidation state cation of zinc. These ingredients included in this report have various reported functions in cosmetics, including hair conditioning agents, skin conditioning agents, cosmetic astringents, cosmetic biocides, preservatives, oral care agents, buffering agents, bulking agents, chelating agents, and viscosity increasing agents. The Panel reviewed the relevant data for these ingredients, and concluded that these 27 ingredients are safe in cosmetics in the present practices of use and concentration described in this safety assessment when formulated to be non-irritating.

化妆品成分安全专家小组(专家小组)对化妆品配方中使用的 27 种无机和有机金属锌盐的安全性进行了评估;这些锌盐特别是锌的 2+ (II) 氧化态阳离子。据报告,本报告中的这些成分在化妆品中具有各种功能,包括头发调理剂、皮肤调理剂、化妆品收敛剂、化妆品杀菌剂、防腐剂、口腔护理剂、缓冲剂、膨松剂、螯合剂和增粘剂。专家小组审查了这些成分的相关数据,得出结论认为,按照本安全评估中所述的现行使用方法和浓度,这 27 种成分在配制成无刺激性的化妆品中是安全的。
{"title":"Safety Assessment of Zinc Salts as Used in Cosmetics.","authors":"Laura N Scott, Monice Fiume, Jinqiu Zhu, Wilma F Bergfeld, Donald V Belsito, Ronald A Hill, Curtis D Klaassen, Daniel C Liebler, James G Marks, Ronald C Shank, Thomas J Slaga, Paul W Snyder, Bart Heldreth","doi":"10.1177/10915818241227124","DOIUrl":"10.1177/10915818241227124","url":null,"abstract":"<p><p>The Expert Panel for Cosmetic Ingredient Safety (Panel) assessed the safety of 27 inorganic and organometallic zinc salts as used in cosmetic formulations; these salts are specifically of the <sup>2+</sup> (II) oxidation state cation of zinc. These ingredients included in this report have various reported functions in cosmetics, including hair conditioning agents, skin conditioning agents, cosmetic astringents, cosmetic biocides, preservatives, oral care agents, buffering agents, bulking agents, chelating agents, and viscosity increasing agents. The Panel reviewed the relevant data for these ingredients, and concluded that these 27 ingredients are safe in cosmetics in the present practices of use and concentration described in this safety assessment when formulated to be non-irritating.</p>","PeriodicalId":14432,"journal":{"name":"International Journal of Toxicology","volume":" ","pages":"5S-69S"},"PeriodicalIF":2.2,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139570305","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Safety Assessment of Alkane Diols as Used in Cosmetics. 化妆品中使用的烷二醇安全性评估。
IF 2.2 4区 医学 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-04-01 Epub Date: 2024-01-04 DOI: 10.1177/10915818231224234
Laura N Scott, Monice Fiume, Wilma F Bergfeld, Donald V Belsito, Ronald A Hill, Curtis D Klaassen, Daniel C Liebler, James G Marks, Ronald C Shank, Thomas J Slaga, Paul W Snyder, Bart Heldreth

The Expert Panel for Cosmetic Ingredient Safety (Panel) assessed the safety of 10 alkane diol ingredients as used in cosmetics. The alkane diols are structurally related to each other as small diols, and most are reported to function in cosmetics as solvents. The Panel reviewed the relevant data for these ingredients, and concluded that seven alkane diols are safe in cosmetics in the present practices of use and concentration described in this safety assessment, but that the available data are insufficient to make a determination of safety for three ingredients, namely 1,4-Butanediol, 2,3-Butanediol, and Octanediol.

化妆品成分安全专家小组(专家小组)评估了化妆品中使用的 10 种烷二醇成分的安全性。这些烷二醇在结构上相互关联,都是小的二元醇,据报道,大多数烷二醇在化妆品中起溶剂作用。专家小组审查了这些成分的相关数据,得出结论认为,按照本安全评估中所述的现行使用方法和浓度,七种烷二醇在化妆品中是安全的,但现有数据不足以确定三种成分(即 1,4-丁二醇、2,3-丁二醇和辛二醇)的安全性。
{"title":"Safety Assessment of Alkane Diols as Used in Cosmetics.","authors":"Laura N Scott, Monice Fiume, Wilma F Bergfeld, Donald V Belsito, Ronald A Hill, Curtis D Klaassen, Daniel C Liebler, James G Marks, Ronald C Shank, Thomas J Slaga, Paul W Snyder, Bart Heldreth","doi":"10.1177/10915818231224234","DOIUrl":"10.1177/10915818231224234","url":null,"abstract":"<p><p>The Expert Panel for Cosmetic Ingredient Safety (Panel) assessed the safety of 10 alkane diol ingredients as used in cosmetics. The alkane diols are structurally related to each other as small diols, and most are reported to function in cosmetics as solvents. The Panel reviewed the relevant data for these ingredients, and concluded that seven alkane diols are safe in cosmetics in the present practices of use and concentration described in this safety assessment, but that the available data are insufficient to make a determination of safety for three ingredients, namely 1,4-Butanediol, 2,3-Butanediol, and Octanediol.</p>","PeriodicalId":14432,"journal":{"name":"International Journal of Toxicology","volume":" ","pages":"70S-131S"},"PeriodicalIF":2.2,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139086791","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mutagenicity Assessment of Homologous Series of Methyl Ester Sulphonates (MES) Using the Bacterial Reverse Mutation (Ames) Test. 利用细菌反向突变(Ames)试验评价甲基酯磺酸盐(MES)同源序列的致突变性。
IF 2.2 4区 医学 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-03-01 Epub Date: 2023-12-04 DOI: 10.1177/10915818231217041
Yusrabbil Amiyati Yusof, Zafarizal Aldrin Azizul Hasan, Zulina Abd Maurad

Methyl ester sulphonate (MES) is an anionic surfactant that is suitable to be used as an active ingredient in household products. Four palm-based MES compounds with various carbon chains, namely C12, C14, C16 and C16/18 MES, were assayed by the in vitro bacterial reverse mutation (Ames) test in the Salmonella typhimurium strains TA98, TA100, TA1535, and TA1537 and the Escherichia coli strain WP2 uvrA, with the aim of establishing the safety data of the compounds, specifically their mutagenicity. The test was also carried out on linear alkylbenzene sulphonate (LAS) for comparison. The plate incorporation method was conducted according to the Organization for Economic Cooperation and Development (OECD) Test Guideline 471. All compounds were tested at five analysable non-cytotoxic concentrations, varying from .001 mg/plate to 5 mg/plate, with and without S-9 metabolic activation. All tested concentrations showed no significant increase in the number of revertant colonies compared to revertant colonies of the negative control. The Ames test indicated that each concentration of C12, C14, C16, C16/18 MES, and LAS used in this study induced neither base-pair substitutions nor frame-shift mutations in the S. typhimurium strains TA98, TA100, TA1535, and TA1537 and the E. coli strain WP2 uvrA. The results showed that C12, C14, C16 and C16/18 MES have no potential mutagenic properties in the presence and absence of S-9 metabolic activation, similarly to LAS. Therefore, the MES is safe to be used as an alternative to petroleum-based surfactants for household cleaning products.

磺酸甲酯(Methyl ester sulphonate, MES)是一种阴离子表面活性剂,适合作为家用产品的活性成分。采用体外细菌反向突变(Ames)试验对4种碳链不同的棕榈基MES化合物C12、C14、C16和C16/18 MES进行了鼠伤寒沙门菌TA98、TA100、TA1535和TA1537以及大肠杆菌WP2 uvrA进行了检测,目的是建立化合物的安全性数据,特别是其致突变性。并对线性烷基苯磺酸盐(LAS)进行了对比试验。钢板掺入法按照经济合作与发展组织(OECD)试验指南471进行。所有化合物在五种可分析的非细胞毒性浓度下进行测试,浓度从0.001 mg/板到5mg /板不等,有无S-9代谢激活。所有测试浓度均显示,与阴性对照的逆转菌落相比,逆转菌落的数量没有显著增加。Ames试验表明,本研究中使用的C12、C14、C16、C16/18 MES和LAS的不同浓度均未引起鼠伤寒沙门氏菌TA98、TA100、TA1535和TA1537以及大肠杆菌WP2 uvrA的碱基对替换和移框突变。结果表明,C12、C14、C16和C16/18 MES在S-9代谢激活和不激活的情况下都没有潜在的致突变特性,与LAS相似。因此,MES是安全的,可以作为家庭清洁产品的石油基表面活性剂的替代品。
{"title":"Mutagenicity Assessment of Homologous Series of Methyl Ester Sulphonates (MES) Using the Bacterial Reverse Mutation (Ames) Test.","authors":"Yusrabbil Amiyati Yusof, Zafarizal Aldrin Azizul Hasan, Zulina Abd Maurad","doi":"10.1177/10915818231217041","DOIUrl":"10.1177/10915818231217041","url":null,"abstract":"<p><p>Methyl ester sulphonate (MES) is an anionic surfactant that is suitable to be used as an active ingredient in household products. Four palm-based MES compounds with various carbon chains, namely C<sub>12</sub>, C<sub>14</sub>, C<sub>16</sub> and C<sub>16/18</sub> MES, were assayed by the in vitro bacterial reverse mutation (Ames) test in the <i>Salmonella typhimurium</i> strains TA98, TA100, TA1535, and TA1537 and the <i>Escherichia coli</i> strain WP2 <u>uvrA</u>, with the aim of establishing the safety data of the compounds, specifically their mutagenicity. The test was also carried out on linear alkylbenzene sulphonate (LAS) for comparison. The plate incorporation method was conducted according to the Organization for Economic Cooperation and Development (OECD) Test Guideline 471. All compounds were tested at five analysable non-cytotoxic concentrations, varying from .001 mg/plate to 5 mg/plate, with and without S-9 metabolic activation. All tested concentrations showed no significant increase in the number of revertant colonies compared to revertant colonies of the negative control. The Ames test indicated that each concentration of C<sub>12</sub>, C<sub>14</sub>, C<sub>16</sub>, C<sub>16/18</sub> MES, and LAS used in this study induced neither base-pair substitutions nor frame-shift mutations in the <i>S. typhimurium</i> strains TA98, TA100, TA1535, and TA1537 and the <i>E</i>. <i>coli</i> strain WP2 <u>uvrA</u>. The results showed that C<sub>12</sub>, C<sub>14</sub>, C<sub>16</sub> and C<sub>16/18</sub> MES have no potential mutagenic properties in the presence and absence of S-9 metabolic activation, similarly to LAS. Therefore, the MES is safe to be used as an alternative to petroleum-based surfactants for household cleaning products.</p>","PeriodicalId":14432,"journal":{"name":"International Journal of Toxicology","volume":" ","pages":"157-164"},"PeriodicalIF":2.2,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138482318","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Copper Chaperone Atox1 Protected the Cochlea From Cisplatin by Regulating the Copper Transport Family and Cell Cycle. 铜伴侣阿托x1通过调节铜转运家族和细胞周期保护耳蜗免受顺铂的侵害。
IF 2.2 4区 医学 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-03-01 Epub Date: 2023-10-20 DOI: 10.1177/10915818231206665
Xubo Chen, Weiren Xiang, Lihua Li, Kai Xu

Antioxidant 1 copper chaperone (Atox1) may contribute to preventing DDP cochlear damage by regulating copper transport family and cell cycle proteins. A rat model of cochlear damage was developed by placing gelatin sponges treated with DDP in the cochlea. HEI-OC1 cells were treated with 133 μM DDP as a cell model. DDP-induced ototoxicity in rats was confirmed by immunofluorescence (IF) imaging. The damage of DDP to HEI-OC1 cells was assessed by using CCK-8, TUNEL, and flow cytometry. The relationship between Atox1, a member of the copper transport protein family, and the damage to in vivo/vitro models was explored by qRT-PCR, western blot, CCK-8, TUNEL, and flow cytometry. DDP had toxic and other side effects causing cochlear damage and promoted HEI-OC1 cell apoptosis and cell cycle arrest. The over-expression of Atox1 (oe-Atox1) was accomplished by transfecting lentiviral vectors into in vitro/vivo models. We found that oe-Atox1 increased the levels of Atox1, copper transporter 1 (CTR1), and SOD3 in HEI-OC1 cells and decreased the expression levels of ATPase copper transporting α (ATP7A) and ATPase copper transporting β (ATP7B). In addition, the transfection of oe-Atox1 decreased cell apoptosis rate and the number of G2/M stage cells. Similarly, the expression of myosin VI and phalloidin of cochlea cells in vivo decreased. Atox1 ameliorated DDP-induced damage to HEI-OC1 cells or rats' cochlea by regulating the levels of members of the copper transport family.

抗氧化剂1铜伴侣(Atox1)可能通过调节铜转运家族和细胞周期蛋白来预防DDP耳蜗损伤。通过在耳蜗中放置DDP处理的明胶海绵,建立了大鼠耳蜗损伤模型。μM DDP处理HEI-OC1细胞作为细胞模型。免疫荧光(IF)成像证实了DDP诱导的大鼠耳毒性。应用CCK-8、TUNEL和流式细胞仪检测DDP对HEI-OC1细胞的损伤。通过qRT-PCR、蛋白质印迹、CCK-8、TUNEL和流式细胞术探讨了铜转运蛋白家族成员Atox1与体内/体外模型损伤之间的关系。DDP具有引起耳蜗损伤的毒性和其他副作用,并促进HEI-OC1细胞凋亡和细胞周期阻滞。Atox1(oe-Atox1)的过表达是通过将慢病毒载体转染到体外/体内模型中来实现的。我们发现oe-Atox1增加了HEI-OC1细胞中Atox1、铜转运蛋白1(CTR1)和SOD3的水平,并降低了ATPase铜转运α(ATP7A)和ATPase铜运输β(ATP7B)的表达水平。此外,oe-Atox1的转染降低了细胞凋亡率和G2/M期细胞的数量。类似地,体内耳蜗细胞的肌球蛋白VI和phaloidin的表达降低。Atox1通过调节铜转运家族成员的水平来改善DDP诱导的HEI-OC1细胞或大鼠耳蜗的损伤。
{"title":"Copper Chaperone Atox1 Protected the Cochlea From Cisplatin by Regulating the Copper Transport Family and Cell Cycle.","authors":"Xubo Chen, Weiren Xiang, Lihua Li, Kai Xu","doi":"10.1177/10915818231206665","DOIUrl":"10.1177/10915818231206665","url":null,"abstract":"<p><p>Antioxidant 1 copper chaperone (Atox1) may contribute to preventing DDP cochlear damage by regulating copper transport family and cell cycle proteins. A rat model of cochlear damage was developed by placing gelatin sponges treated with DDP in the cochlea. HEI-OC1 cells were treated with 133 μM DDP as a cell model. DDP-induced ototoxicity in rats was confirmed by immunofluorescence (IF) imaging. The damage of DDP to HEI-OC1 cells was assessed by using CCK-8, TUNEL, and flow cytometry. The relationship between Atox1, a member of the copper transport protein family, and the damage to <i>in vivo</i>/<i>vitro</i> models was explored by qRT-PCR, western blot, CCK-8, TUNEL, and flow cytometry. DDP had toxic and other side effects causing cochlear damage and promoted HEI-OC1 cell apoptosis and cell cycle arrest. The over-expression of Atox1 (oe-Atox1) was accomplished by transfecting lentiviral vectors into <i>in vitro</i>/<i>vivo</i> models. We found that oe-Atox1 increased the levels of Atox1, copper transporter 1 (CTR1), and SOD3 in HEI-OC1 cells and decreased the expression levels of ATPase copper transporting α (ATP7A) and ATPase copper transporting β (ATP7B). In addition, the transfection of oe-Atox1 decreased cell apoptosis rate and the number of G2/M stage cells. Similarly, the expression of myosin VI and phalloidin of cochlea cells <i>in vivo</i> decreased. Atox1 ameliorated DDP-induced damage to HEI-OC1 cells or rats' cochlea by regulating the levels of members of the copper transport family.</p>","PeriodicalId":14432,"journal":{"name":"International Journal of Toxicology","volume":" ","pages":"134-145"},"PeriodicalIF":2.2,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49677417","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Triggering Receptor Expressed on Myeloid Cells 2 Deficiency Exacerbates Methamphetamine-Induced Activation of Microglia and Neuroinflammation. 髓细胞2缺乏触发受体表达加剧甲基苯丙胺诱导的小胶质细胞活化和神经炎症。
IF 2.2 4区 医学 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-03-01 Epub Date: 2023-11-25 DOI: 10.1177/10915818231216397
Yanxia Peng, Genmeng Yang, Shangwen Wang, Wanrong Lin, Lihua Zhu, Wenjuan Dong, Baoyu Shen, Qianyun Nie, Shijun Hong, Lihua Li

Methamphetamine (METH) is a highly addictive psychostimulant and one of the most widely abused drugs worldwide. The continuous use of METH eventually leads to neurotoxicity and drug addiction. Studies have shown that neurotoxicity is strongly associated with METH-induced neuroinflammation, and microglia are the key drivers of neuroinflammation. Triggering receptor expressed on myeloid cells 2 (TREM2) is reported to play a key role in activation of microglia and neuroinflammation. Yet, the molecular mechanisms by which METH causes neuroinflammation and neurotoxicity remain elusive. In the current study, we investigated the role of TREM2 in neuroinflammation induced by METH in BV2 cells and the wild-type (WT) C57BL/6J mice, CX3CR1GFP/+ transgenic mice, and TREM2 knockout (KO) mice. Postmortem samples from the frontal cortex of humans with a history of METH use were also analyzed to determine the levels of TREM2, TLR4, IBA1, and IL-1β. The expression levels of TREM2, TLR4, IBA1, IL-1β, iNOS, and Arg-1 were then assessed in the BV2 cells and frontal cortex of mice and human METH users. Results revealed that the expression levels of TREM2, TLR4, IBA1, and IL-1β were significantly elevated in METH-using individuals and BV2 cells. Microglia were clearly activated in the frontal cortex of WT C57BL/6 mice and CX3CR1GFP/+ transgenic mice, and the protein levels of IBA1, TREM2, TLR4, and IL-1β were elevated in the METH-induced mouse models. Moreover, TREM2-KO mice showed further increased microglial activation, neuroinflammation, and excitotoxicity induced by METH. Thus, these findings suggest that TREM2 may be a target for regulating METH-induced neuroinflammation.

甲基苯丙胺是一种高度成瘾性的精神兴奋剂,是世界上滥用最广泛的药物之一。持续使用冰毒最终会导致神经毒性和药物成瘾。研究表明,神经毒性与甲基苯丙胺诱导的神经炎症密切相关,而小胶质细胞是神经炎症的关键驱动因素。髓样细胞上表达的触发受体2 (TREM2)在小胶质细胞的激活和神经炎症中起关键作用。然而,甲基安非他明引起神经炎症和神经毒性的分子机制仍然难以捉摸。在目前的研究中,我们调查的角色TREM2冰毒BV2细胞引起的神经炎症和野生型(WT) C57BL / 6 j小鼠,CX3CR1GFP / +转基因老鼠,TREM2基因敲除小鼠(KO)。研究人员还分析了有冰毒使用史的人的死后额叶皮层样本,以确定TREM2、TLR4、IBA1和IL-1β的水平。然后评估TREM2、TLR4、IBA1、IL-1β、iNOS和Arg-1在小鼠和人类冰毒使用者BV2细胞和额叶皮层中的表达水平。结果显示,使用meth的个体和BV2细胞中TREM2、TLR4、IBA1和IL-1β的表达水平显著升高。WT C57BL/6小鼠和CX3CR1GFP/+转基因小鼠额叶皮层小胶质细胞明显激活,meth诱导小鼠模型中IBA1、TREM2、TLR4和IL-1β蛋白水平升高。此外,TREM2-KO小鼠显示出甲基安非他明诱导的进一步增加的小胶质细胞激活、神经炎症和兴奋毒性。因此,这些发现表明TREM2可能是调节甲基甲醚诱导的神经炎症的靶点。
{"title":"Triggering Receptor Expressed on Myeloid Cells 2 Deficiency Exacerbates Methamphetamine-Induced Activation of Microglia and Neuroinflammation.","authors":"Yanxia Peng, Genmeng Yang, Shangwen Wang, Wanrong Lin, Lihua Zhu, Wenjuan Dong, Baoyu Shen, Qianyun Nie, Shijun Hong, Lihua Li","doi":"10.1177/10915818231216397","DOIUrl":"10.1177/10915818231216397","url":null,"abstract":"<p><p>Methamphetamine (METH) is a highly addictive psychostimulant and one of the most widely abused drugs worldwide. The continuous use of METH eventually leads to neurotoxicity and drug addiction. Studies have shown that neurotoxicity is strongly associated with METH-induced neuroinflammation, and microglia are the key drivers of neuroinflammation. Triggering receptor expressed on myeloid cells 2 (TREM2) is reported to play a key role in activation of microglia and neuroinflammation. Yet, the molecular mechanisms by which METH causes neuroinflammation and neurotoxicity remain elusive. In the current study, we investigated the role of TREM2 in neuroinflammation induced by METH in BV2 cells and the wild-type (WT) C57BL/6J mice, CX3CR1<sup>GFP/+</sup> transgenic mice, and TREM2 knockout (KO) mice. Postmortem samples from the frontal cortex of humans with a history of METH use were also analyzed to determine the levels of TREM2, TLR4, IBA1, and IL-1β. The expression levels of TREM2, TLR4, IBA1, IL-1β, iNOS, and Arg-1 were then assessed in the BV2 cells and frontal cortex of mice and human METH users. Results revealed that the expression levels of TREM2, TLR4, IBA1, and IL-1β were significantly elevated in METH-using individuals and BV2 cells. Microglia were clearly activated in the frontal cortex of WT C57BL/6 mice and CX3CR1<sup>GFP/+</sup> transgenic mice, and the protein levels of IBA1, TREM2, TLR4, and IL-1β were elevated in the METH-induced mouse models. Moreover, TREM2-KO mice showed further increased microglial activation, neuroinflammation, and excitotoxicity induced by METH. Thus, these findings suggest that TREM2 may be a target for regulating METH-induced neuroinflammation.</p>","PeriodicalId":14432,"journal":{"name":"International Journal of Toxicology","volume":" ","pages":"165-176"},"PeriodicalIF":2.2,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138434038","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
International Journal of Toxicology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1